Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia (XANAP)

Bayer

Status: Completed

Conditions: Atrial Fibrillation

Treatments: Drug: Rivaroxaban (Xarelto, BAY59-7939)

Study type: Observational

Funder types: Industry

Identifiers

NCT01750788

16371

XA1205 (Other Identifier)

Details and patient eligibility

About

This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.

Enrollment: 2,297 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS (Central Nervous System) systemic embolism, and who consent to participate in the study.

Trial design

2,297 participants in 1 patient group

Group 1

Treatment:

Drug: Rivaroxaban (Xarelto, BAY59-7939)